TSE:CNJ - Cangene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeC$2.05 - C$3.61
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cangene Corporation (Cangene) is a biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company's Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company's products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG). In February 2014, Emergent BioSolutions Inc completed the acquisition of Cangene.

Receive CNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for CNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
Phone+1-204-2754200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Cangene (TSE:CNJ) Frequently Asked Questions

What is Cangene's stock symbol?

Cangene trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CNJ."

Has Cangene been receiving favorable news coverage?

News coverage about CNJ stock has trended negative recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cangene earned a news impact score of -2.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are Cangene's key executives?

Cangene's management team includes the folowing people:
  • R. Craig Baxter, Chairman of the Board
  • John A. Sedor, President, Chief Executive Officer, Director (Age 72)
  • Jeffrey Lamothe, Chief Financial Officer
  • Gary Clyde Floyd, Chief Operating Officer
  • Laura Saward, Chief Scientific Officer
  • Michael D. Adelman, Vice President - Commercial Operations
  • Francis St. Hilaire, Vice President, General Counsel, Secretary
  • Les Deezar, Vice President - Human Resources
  • Chris Sinclair, Vice President - Strategic Planning
  • Kevin G. Taylor, Vice President - Business Development

How do I buy shares of Cangene?

Shares of CNJ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How can I contact Cangene?

Cangene's mailing address is 155 Innovation Dr, WINNIPEG, MB R3T 5Y3, Canada. The biopharmaceutical company can be reached via phone at +1-204-2754200.


MarketBeat Community Rating for Cangene (TSE CNJ)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Cangene and other stocks. Vote "Outperform" if you believe CNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel